Moderna (MRNA) Stock Overview
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MRNA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.11 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.17 |
| 1 Month Change | 43.05% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -84.75% |
| 5 Year Change | n/a |
| Change since IPO | -76.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRNA | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 14.2% | -1.4% | 0.9% |
| 1Y | n/a | 13.7% | 10.7% |
Return vs Industry: Insufficient data to determine how MRNA performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how MRNA performed against the Swiss Market.
Price Volatility
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.2% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: MRNA's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine MRNA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,800 | Stéphane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis.
Moderna, Inc. Fundamentals Summary
| MRNA fundamental statistics | |
|---|---|
| Market cap | CHF 10.00b |
| Earnings (TTM) | -CHF 2.48b |
| Revenue (TTM) | CHF 1.78b |
Is MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNA income statement (TTM) | |
|---|---|
| Revenue | US$2.23b |
| Cost of Revenue | US$4.63b |
| Gross Profit | -US$2.40b |
| Other Expenses | US$714.00m |
| Earnings | -US$3.12b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.97 |
| Gross Margin | -107.62% |
| Net Profit Margin | -139.61% |
| Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 01:17 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moderna, Inc. is covered by 45 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Huidong Wang | Barclays |
| Harry Gillis | Berenberg |